https://www.selleckchem.com/Bcl-2.html
Iron oxide-based nanoparticles have been modified in their core with holmium(III) in an amount affecting only slightly their magnetic properties. Nanoparticles were conjugated covalently with biomolecule of trastuzumab (Herceptin®), the monoclonal antibody that recognizes cancer cells overexpressing HER2 receptors targeting such nanoparticles to the specified tumor tissues. Systematic studies of Ho3+-doped bioconjugates were carried out as a preliminary step for future replacement of 'cold' Ho with 166Ho radionuclide, emitting 'soft' beta(-) radia
Like
Comment
Share
